Home Methylation -Epigenetics JMJD

JMJD

Isoform-selective Products

JMJD Products

  • All (10)
  • JMJD Inhibitors (10)
  • New JMJD Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Nat Cell Biol, 2024, 26(7):1165-1175
J Clin Invest, 2024, 134(24)e173403
J Clin Invest, 2024, 134(1)e163964
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor with a half-maximal inhibitory concentration (IC50) of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
Cancer Cell, 2023, 41(6):1118-1133.e12
mBio, 2022, 13(1):e0337721
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
Viruses, 2023, 15(1)163
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Front Immunol, 2024, 15:1308978
Cell Biol Toxicol, 2024, 40(1):99
S7581 GSK J1 GSK-J1 is a highly potent inhibitor of H3K27 histone demethylase JMJD3 (KDM6B) and UTX (KDM6A) with IC50 of 60 nM in cell-free assays for JMJD3 (KDM6B) , respectively, >10-fold selectivity over other tested demethylases, with IC50 of 0.95μM and 1.76μM towards JARID1B/C.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Cell Rep Med, 2023, 4(5):101026
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Nat Cell Biol, 2024, 26(7):1165-1175
J Clin Invest, 2024, 134(24)e173403
J Clin Invest, 2024, 134(1)e163964
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor with a half-maximal inhibitory concentration (IC50) of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
Cancer Cell, 2023, 41(6):1118-1133.e12
mBio, 2022, 13(1):e0337721
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
Viruses, 2023, 15(1)163
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Front Immunol, 2024, 15:1308978
Cell Biol Toxicol, 2024, 40(1):99
S7581 GSK J1 GSK-J1 is a highly potent inhibitor of H3K27 histone demethylase JMJD3 (KDM6B) and UTX (KDM6A) with IC50 of 60 nM in cell-free assays for JMJD3 (KDM6B) , respectively, >10-fold selectivity over other tested demethylases, with IC50 of 0.95μM and 1.76μM towards JARID1B/C.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Cell Rep Med, 2023, 4(5):101026
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.

Choose Selective JMJD Inhibitors

Tags: JMJD inhibitor | JMJD modulator | JMJD chemical